ERBB2 and neoplasm: Lapatinib is a dual small-molecule TKI which blocks EGFR type 1 (EGFR1, also known as HER1) and HER2 tyrosine kinase activities, resulting in the inhibition of intracellular signaling and suppressing of tumor proliferation [17].